

Figure S1 The expression of *FHL2* and *CD146*. (A) *FHL2* mRNA expression in A549 and H226 cells upon transfection with Flag-*FHL2* plasmids. (B) *FHL2* mRNA expression in A549 and H226 cells upon transfection with siRNA targeting *FHL2*. (C) Positive correlation between *FHL2* and *CD146* mRNA expression in NSCLC tissues from TCGA database. ***, P<0.001. *FHL2*, four-and-a-half LIM-domain protein 2; CM, conditioned medium; TPM, transcript per million; TCGA, The Cancer Genome Atlas; mRNA, messenger RNA; NSCLC, non-small cell lung cancer.




Figure S2 Schematic diagram of the proposed underlying mechanisms involved in *FHL2*-induced NSCLC proliferation, angiogenesis, and vascular permeability. NSCLC, non-small cell lung cancer; *FHL2*, four-and-a-half LIM-domain protein 2; VEGFA, vascular endothelial growth factor A; HUVEC, human umbilical vein endothelial cell; mRNA, messenger RNA.

Table S1 The primers for qPCR

Gene	Primers
<i>FHL2</i>	F: GAGGGGTCACTTACCGGGAA R: TTAAAGCAGTCGTTATGCCACT
<i>VEGFA</i>	F: TTGCTGCTCTACCTCCACCAT R: GGTGATGTTGGACTCCTCAGTG
<i>VEGFB</i>	F: CCGGAAGCTGCGAAGGTGACA R: GGGAGACAAGGGATGGCAGAAGAG
<i>VEGFC</i>	F: AGCTCGGATGTCCGGTTTC R: GCGTTCCCAACTTGCAG
<i>VEGFD</i>	F: GCAGCCCTAGAGAACGTG R: AGGTGCTGGTGTTCATACAGAT
<i>FGF</i>	F: AGAAGAGCGACCCTCACATCA R: CGGTTAGCACACACTCCTTTG
<i>PGF</i>	F: GTTCAGCCCATCCTGTGTCT R: AACGTGCTGAGAGAACGTCA
<i>MMP2</i>	F: AATCCCACCAACCCCTCAGAG R: GTGCCCTCTTGAGACAGTCT
<i>CXCL9</i>	F: AAGCAGCCAAGTCGGTTAGT R: CAGCAGTGTGAGCAGTGATT
<i>THBS1</i>	F: GTCATACAAACACTCCCACGC R: CCAGGGCATAGGTAGAAGCT
β -actin	F: CACGAAACTACCTTCAACTCC R: CATACTCCTGCTTGCTGATC

qPCR, quantitative polymerase chain reaction.